Zabek Piotr, Opoka-Kegler Jolanta, Baka Magdalena, Dyda Tomasz, Stańczak Grzegorz P, Stańczak Janusz J
Molecular Diagnostics Laboratory, Hospital for Infectious Diseases, Warsaw, Poland.
Przegl Epidemiol. 2013;67(3):411-3, 521-3.
The aim of this study was to evaluate prevalence of hepatitis C virus (HCV) harbouring mutations associated with decreased susceptibility to protease inhibitors (Boceprevir/Telaprevir) among Polish untreated patients infected with HCV genotype 1.
Population sequencing was used, sequencing data were interpreted by web based geno2pheno algorithm. A total of 91 serum samples were obtained from patients infected with HCV genotype 1, admitting Outpatient Clinics of Hospital of Infectious Diseases, Warsaw.
Sequencing analysis of the NS3 protease catalytic domain was successful in 85 out of 91 subjects. In seventy three (85.9%) out of 85 samples wild-type HCV was detected; in 12 (14.1%) samples mutations associated with clinically observed Boceprevir/Telaprevir-decreased susceptibility were detected.
Obtained results document the presence of HCV strains harbouring protease inhibitors (PIs) resistance-associated mutations among Polish therapy-naïve patients. The determined prevalence of drug resistant HCV variants is 14.1%. Further and continuous surveillance is necessary to estimate how preexisting and emerging drug resistance mutations influence clinical outcome in triple-therapy experienced patients.
本研究旨在评估波兰未接受治疗的丙型肝炎病毒（HCV）基因1型感染者中携带与蛋白酶抑制剂（博赛匹韦/特拉匹韦）敏感性降低相关突变的HCV流行情况。
采用群体测序法，测序数据通过基于网络的geno2pheno算法进行解读。从华沙传染病医院门诊收治的HCV基因1型感染患者中获取了91份血清样本。
91名受试者中有85名成功完成了NS3蛋白酶催化结构域的测序分析。在85份样本中，73份（85.9%）检测到野生型HCV；12份（14.1%）样本检测到与临床上观察到的博赛匹韦/特拉匹韦敏感性降低相关的突变。
研究结果证明在波兰未经治疗的患者中存在携带蛋白酶抑制剂（PIs）耐药相关突变的HCV毒株。耐药HCV变异株的确定流行率为14.1%。需要进一步持续监测，以评估既往存在和新出现的耐药突变如何影响接受三联疗法患者的临床结局。
